220 related articles for article (PubMed ID: 8667063)
21. Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression.
Moretti JL; Azaloux H; Boisseron D; Kouyoumdjian JC; Vilcoq J
Eur J Nucl Med; 1996 Aug; 23(8):980-6. PubMed ID: 8753690
[TBL] [Abstract][Full Text] [Related]
22. Determination and prediction of P-glycoprotein and multidrug-resistance-related protein expression in breast cancer with double-phase technetium-99m sestamibi scintimammography. Visual and quantitative analyses.
Kim IJ; Bae YT; Kim SJ; Kim YK; Kim DS; Lee JS
Oncology; 2006; 70(6):403-10. PubMed ID: 17237619
[TBL] [Abstract][Full Text] [Related]
23. Application of SPET using technetium-99m sestamibi in brain tumours and comparison with expression of the MDR-1 gene: is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-sestamibi SPET?
Yokogami K; Kawano H; Moriyama T; Uehara H; Sameshima T; Oku T; Goya T; Wakisaka S; Nagamachi S; Jinnouchi S; Tamura S
Eur J Nucl Med; 1998 Apr; 25(4):401-9. PubMed ID: 9553170
[TBL] [Abstract][Full Text] [Related]
24. Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG.
Krasznai ZT; Tóth A; Mikecz P; Fodor Z; Szabó G; Galuska L; Hernádi Z; Goda K
Eur J Pharm Sci; 2010 Dec; 41(5):665-9. PubMed ID: 20869436
[TBL] [Abstract][Full Text] [Related]
25. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.
Ciarmiello A; Del Vecchio S; Silvestro P; Potena MI; Carriero MV; Thomas R; Botti G; D'Aiuto G; Salvatore M
J Clin Oncol; 1998 May; 16(5):1677-83. PubMed ID: 9586878
[TBL] [Abstract][Full Text] [Related]
26. Reversal of multidrug resistance: lessons from clinical oncology.
Bates SF; Chen C; Robey R; Kang M; Figg WD; Fojo T
Novartis Found Symp; 2002; 243():83-96; discussion 96-102, 180-5. PubMed ID: 11990784
[TBL] [Abstract][Full Text] [Related]
27. 99mTc-exametazime as a breast tumor-seeking agent: comparison with 99mTc-sestamibi.
Wilczek B; Svensson L; Danielsson R; Celebiouglu F; Larsson SA; Jacobsson H
J Nucl Med; 2004 Dec; 45(12):2040-4. PubMed ID: 15585479
[TBL] [Abstract][Full Text] [Related]
28. Expression of drug resistance protein related to Tc-99m MIBI breast imaging.
Sun SS; Hsieh JF; Tsai SC; Ho YJ; Kao CH
Anticancer Res; 2000; 20(3B):2021-5. PubMed ID: 10928145
[TBL] [Abstract][Full Text] [Related]
29. The multidrug resistance of in vitro tumor cell lines derived from human breast carcinoma MCF-7 does not influence pentavalent technetium-99m-dimercaptosuccinic Acid uptake.
Denoyer D; Perek N; Le Jeune N; Frère D; Dubois F
Cancer Biother Radiopharm; 2003 Oct; 18(5):791-801. PubMed ID: 14629827
[TBL] [Abstract][Full Text] [Related]
30. Technetium-99m sestamibi uptake in human breast carcinoma cell lines displaying glutathione-associated drug-resistance.
Kabasakal L; Ozker K; Hayward M; Akansel G; Griffith O; Isitman AT; Hellman R; Collier D
Eur J Nucl Med; 1996 May; 23(5):568-70. PubMed ID: 8698063
[TBL] [Abstract][Full Text] [Related]
31. Comparative 99mTc-sestamibi and 3H-daunomycin uptake in human carcinoma cells: relation to the MDR phenotype and effects of reversing agents.
Cayre A; Moins N; Finat-Duclos F; Maublant J; Verrelle P
J Nucl Med; 1999 Apr; 40(4):672-6. PubMed ID: 10210228
[TBL] [Abstract][Full Text] [Related]
32. 99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis.
Yüksel M; Cermik TF; Doğanay L; Karlikaya C; Cakir E; Salan A; Berkarda S
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):876-81. PubMed ID: 12111127
[TBL] [Abstract][Full Text] [Related]
33. Detection of P-glycoprotein activity in endotoxemic rats by 99mTc-sestamibi imaging.
Wang JH; Scollard DA; Teng S; Reilly RM; Piquette-Miller M
J Nucl Med; 2005 Sep; 46(9):1537-45. PubMed ID: 16157538
[TBL] [Abstract][Full Text] [Related]
34. 99mTc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma patients.
Fallahi B; Beiki D; Mousavi SA; Gholamrezanezhad A; Eftekhari M; Fard-Esfahani A; Alimoghaddam K; Mirpour S; Eskandarian A; Saghari M
Hell J Nucl Med; 2009; 12(3):255-9. PubMed ID: 19936339
[TBL] [Abstract][Full Text] [Related]
35. The value of Tc-99m tetrofosmin scintimammography in the assessment of P-glycoprotein in patients with breast cancer.
Silov G; Erdoğan Z; Özdal A; Tutuş A; Tekin Y; Karaman H; Turhal Ö
Hell J Nucl Med; 2013; 16(3):218-22. PubMed ID: 24137583
[TBL] [Abstract][Full Text] [Related]
36. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.
Agrawal M; Abraham J; Balis FM; Edgerly M; Stein WD; Bates S; Fojo T; Chen CC
Clin Cancer Res; 2003 Feb; 9(2):650-6. PubMed ID: 12576431
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo tracer characteristics of an established multidrug-resistant human colon cancer cell line.
Lorke DE; Krüger M; Buchert R; Bohuslavizki KH; Clausen M; Schumacher U
J Nucl Med; 2001 Apr; 42(4):646-54. PubMed ID: 11337555
[TBL] [Abstract][Full Text] [Related]
38. P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy.
Kostakoglu L; Guc D; Canpinar H; Kars A; Alper E; Kiratli P; Hayran M; Gündüz U; Kansu E
J Nucl Med; 1998 Jul; 39(7):1191-7. PubMed ID: 9669392
[TBL] [Abstract][Full Text] [Related]
39. The effect of chemotherapy on the uptake of technetium-99m sestamibi in breast cancer.
Cwikla JB; Buscombe JR; Barlow RV; Kelleher SM; Parbhoo SP; Crow J; Deery A; Jones AL; Hilson AJ
Eur J Nucl Med; 1997 Sep; 24(9):1175-8. PubMed ID: 9283114
[TBL] [Abstract][Full Text] [Related]
40. Comparison of (99m)Tc-sestamibi and doxorubicin to monitor inhibition of P-glycoprotein function.
Muzzammil T; Moore MJ; Hedley D; Ballinger JR
Br J Cancer; 2001 Feb; 84(3):367-73. PubMed ID: 11161402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
